Nixon Peabody Trust Co. Has $506,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Nixon Peabody Trust Co. lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 16.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,074 shares of the company’s stock after purchasing an additional 433 shares during the period. Nixon Peabody Trust Co.’s holdings in Zoetis were worth $506,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its stake in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $30,000. Murphy & Mullick Capital Management Corp acquired a new position in shares of Zoetis during the 4th quarter worth about $44,000. Finally, Asset Planning Inc acquired a new position in shares of Zoetis during the 4th quarter worth about $58,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This represents a 2.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.18% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $170.40 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $75.86 billion, a P/E ratio of 31.15, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The firm has a 50-day moving average price of $157.04 and a two-hundred day moving average price of $164.43.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.38 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date is Friday, July 18th. Zoetis’s dividend payout ratio is currently 35.91%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a research note on Monday, May 12th. Stifel Nicolaus reduced their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average target price of $212.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.